Approximately 72% of BRCA1 carriers and 22–34% of BRCA2 and PALB2 carriers diagnosed with breast cancer present with triple-negative breast cancer (TNBC) [3, 4] a particularly aggressive biologic subtype that almost always necessitates chemotherapy even if tumors are small at diagnosis [5]. This evidence concerns the gene BRCA2 and breast cancer.